Literature DB >> 11320205

The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

T Kumagai1, J G Davis, T Horie, D M O'Rourke, M I Greene.   

Abstract

The extracellular domain of p185(c-neu) can be viewed as a complex structure of four subdomains, two of which are cysteine-rich subdomains. We have investigated the contribution of these distinct p185(c-neu) extracellular subdomains to p185/epidermal growth factor receptor (EGFR) heteromer formation and EGF-induced heteromeric signaling. Our studies indicate that at least two separate p185 subdomains, a region spanning subdomains I and II and subdomain IV are involved in association of p185 with the EGFR. We also demonstrated that subdomain IV reduced the heteromeric signaling and transforming activities induced by EGF after associating with EGFR. When 126 aa were deleted from subdomain IV, this small subdomain IV-derived fragment could still lead to heterodimers with EGFR and suppress EGF-induced mitogen-activated protein kinase activation and subsequent transformation abilities. These data provide information about trans-inhibitory mechanisms of mutant p185 species and also indicate that both the entire and a part of subdomain IV may represent a therapeutic target for erbB-overexpressing tumors. Finally, these studies define a basic feature of receptor-receptor associations that are determined by cystine-knot containing subdomains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320205      PMCID: PMC33246          DOI: 10.1073/pnas.071060598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

2.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Authors:  R Pinkas-Kramarski; L Soussan; H Waterman; G Levkowitz; I Alroy; L Klapper; S Lavi; R Seger; B J Ratzkin; M Sela; Y Yarden
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

Review 3.  Oncoprotein networks.

Authors:  T Hunter
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 4.  A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.

Authors:  K L Carraway; L C Cantley
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

Review 5.  Structure-based design of immunologically active therapeutic peptides.

Authors:  R Murali; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

6.  Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains.

Authors:  D M O'Rourke; X Qian; H T Zhang; J G Davis; E Nute; J Meinkoth; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.

Authors:  X Qian; D M O'Rourke; H Zhao; M I Greene
Journal:  Oncogene       Date:  1996-11-21       Impact factor: 9.867

8.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

Authors:  P M Siegel; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.

Authors:  X Qian; W C Dougall; M E Hellman; M I Greene
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

10.  Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor.

Authors:  C W Ward; P A Hoyne; R H Flegg
Journal:  Proteins       Date:  1995-06
View more
  8 in total

1.  Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation.

Authors:  Toru Kumagai; Makoto Katsumata; Akihiro Hasegawa; Keiji Furuuchi; Toshiki Funakoshi; Ichiro Kawase; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

2.  Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age.

Authors:  Jörg J Jacoby; April Kalinowski; Mu-Gen Liu; Samuel S-M Zhang; Qian Gao; Gui-Xuan Chai; Lan Ji; Yoshiki Iwamoto; En Li; Michael Schneider; Kerry S Russell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

3.  Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line.

Authors:  Shiaw-Lin Wu; Allen D Taylor; Qiaozhen Lu; Samir M Hanash; Hogune Im; Michael Snyder; William S Hancock
Journal:  Mol Cell Proteomics       Date:  2013-01-31       Impact factor: 5.911

4.  Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs.

Authors:  Nira Ben-Jonathan; Shenglin Chen; Joseph A Dunckley; Christopher LaPensee; Sanjay Kansra
Journal:  Endocrinology       Date:  2008-10-01       Impact factor: 4.736

5.  Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.

Authors:  Emy Behmoaram; Krikor Bijian; Su Jie; Yingjie Xu; Andrew Darnel; Tarek A Bismar; Moulay A Alaoui-Jamali
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

6.  The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

Authors:  Arthur B McKie; Sebastian Vaughan; Elisa Zanini; Imoh S Okon; Louay Louis; Camila de Sousa; Mark I Greene; Qiang Wang; Roshan Agarwal; Dmitry Shaposhnikov; Joshua L C Wong; Hatice Gungor; Szymon Janczar; Mona El-Bahrawy; Eric W-F Lam; Naomi E Chayen; Hani Gabra
Journal:  Cancer Discov       Date:  2012-02       Impact factor: 39.397

7.  Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.

Authors:  Rita Nahta
Journal:  ISRN Oncol       Date:  2012-11-22

Review 8.  Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Authors:  Alan Berezov; Mark I Greene; Ramachandran Murali
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.